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We examined the pharmacokinetic properties of vancomycin conjugated to a bone-targeting agent (BT) with high affinity for
hydroxyapatite after systemic intravenous administration. The results confirm enhanced persistence of BT-vancomycin in
plasma and enhanced accumulation in bone relative to vancomycin. This suggests that BT-vancomycin may be a potential car-
rier for the systemic targeted delivery of vancomycin in the treatment of bone infections, potentially reducing the reliance on
surgical debridement to achieve the desired therapeutic outcome.
Osteomyelitis is defined as any inflammatory process in bone,the most common cause of which is infection. Although
many bacterial pathogens have been associated with osteomyeli-
tis, Staphylococcus aureus is the predominant cause and the patho-
gen responsible for the most serious forms of bone infection (1).
Given the increasing prevalence of S. aureus strains resistant to
methicillin (2), vancomycin remains the most commonly used
antibiotic for the treatment of these infections (3). While true
vancomycin resistance is rare, S. aureus strains with reduced sus-
ceptibility are common and often arise as a consequence of the
prolonged periods of vancomycin therapy required to treat bone
infections (1, 4). Vancomycin acts by inhibiting bacterial cell wall
biosynthesis (5, 6) and is a large hydrophilic molecule that has
limited penetration into bone and therefore low bone bioavail-
ability when administered systemically (7). These factors empha-
size the need to developmethods to enhance delivery of vancomy-
cin to bone in the treatment of osteomyelitis. One way to
accomplish this is to employ local antibiotic delivery, which while
useful suffers from inherent limitations, not the least being the
ability to gain direct access to the infection site (8–16). Thus, one
of the major challenges to improve therapeutic outcomes for os-
teomyelitis patients is to develop methods for the systemic deliv-
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FIG 1 Structures of vancomycin (left) and BT-vancomycin (right).
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ery of vancomycin, and potentially other antibiotics, in sufficient
concentrations to achieve the desired therapeutic effect.
Previous studies in our laboratories have led to the develop-
ment of bone-targeting agents (BT) based on their high affinity for
hydroxyapatite and an enhanced tendency to accumulate in bone
(17). We demonstrated that these compounds can be conjugated
to vancomycin via a modified polyethylene glycol (PEG) linker
(Fig. 1) to form BT-2-minipeg-2-vancomycin (BT-vancomycin)
(18–20). Previous in vitro studies confirmed that the MICs of
BT-vancomycin against methicillin-resistant andmethicillin-sus-
ceptible S. aureus are comparable to those of vancomycin alone
and that BT-vancomycin binds to hydroxyapatite to a greater ex-
tent than vancomycin (21). The objective of the present study was
to define the pharmacokinetic (PK) profiles of vancomycin and
BT-vancomycin after systemic administration via intravenous
(i.v.) or intraperitoneal (i.p.) routes and to determine the plasma
and bone content of vancomycin versus BT-vancomycin.
All experimental animal protocols were in strict accordance
with theNIH “Guide for theCare andUse of Laboratory Animals”
(24) and were approved by the Institutional Animal Care and Use
Committees at the University of Kentucky, Lexington, KY, and
Mayo Clinic, Rochester, MN. Thirty-five rats received a single i.v.
injection via the tail vein of either vancomycin HCl (50 mg/kg of
body weight) or BT-vancomycin (63.85 mg/kg; molar equivalent
of 50 mg/kg of vancomycin HCl). Twenty rats were given an i.p.
injection of either vancomycin HCl (50 mg/kg) or BT-vancomy-
cin (63.85 mg/kg) twice daily for a total of seven doses. BT-van-
comycin and vancomycin levels in plasma and bone were deter-
mined by liquid chromatography-tandem mass spectrometry
(LC/MS-MS).
Bone samples (frozen tibiae) were pulverized, and the crushed
bones were weighed, placed into 2-ml tubes, and stored at80°C
for further analysis. Analysis of vancomycin and BT-vancomycin
was carried out using a Shimadzu LC unit coupled to an ABI
4000-Qtrap hybrid linear ion trap triple-quadrupole mass spec-
trometer in the multiple reaction monitoring (MRM) mode. Tei-
coplanin was used as an internal standard.
PK analysis was performed using data from individual rats, for
which the mean and standard error of the mean (SEM) were cal-
culated for each group. PK parameters were estimated using a
noncompartmental model (Phoenix WinNonlin, Professional,
version 6.2; Pharsight, Mountain View, CA). The levels of vanco-
mycin and BT-vancomycin in plasma peaked at 13.00 1.96 and
41.22  8.71 M, respectively, 1 h after administration (Fig. 2).
The concentration of BT-vancomycin in plasma declined to its
lowest levels (0.07  0.02 M) at 168 h, while vancomycin
reached its lowest level 12 h after i.v. administration (Fig. 2). Com-
pared to the peak concentrations in plasma, peak concentrations
in bonewere delayed, with peak concentrations occurring 6 h after
i.v. administration (Fig. 3). The amount of BT-vancomycin in
bone was approximately 5-fold higher than that of vancomycin
during the initial 12-h period but increased progressively to ap-
proximately 47-fold at 168 h (Table 1).
Increased accumulation of BT-vancomycin was also con-
firmed after i.p. administration of seven doses of 50 mg/kg of
vancomycin or the molar equivalent of BT-vancomycin at 12-h
intervals. The ratios of BT-vancomycin to vancomycin were 7.8,
7.4, and 47.7 at 1, 6, and 12 h after the last i.p. administration
FIG 2 Plasma concentration-time profile of vancomycin (circles) and BT-
vancomycin (squares) after i.v. administration of 50 mg/kg vancomycin or
63.85 mg/kg BT-vancomycin (molar equivalent to 50 mg/kg vancomycin).
Results are themean SEM (n 5 rats). *, significantly higher than results for
vancomycin, P  0.05; **, significantly higher than results for vancomycin,
P 0.01; ***, significantly higher than results for vancomycin, P 0.0001.
FIG 3 Concentration-time profile in bone of vancomycin (circles) and BT-
vancomycin (squares) after i.v. administration of vancomycin (50 mg/kg) or
BT-vancomycin (63.85 mg/kg). Results are the mean  SEM (n  5 rats per
group). *, significantly higher than results for vancomycin, P  0.05; **, sig-
nificantly higher than results for vancomycin, P  0.01; ***, significantly
higher than results for vancomycin, P 0.001.
TABLE 1 Comparative concentrations of vancomycin and
BT-vancomycin in bone after i.v. administration of 50 mg/kg
vancomycin or 63.85 mg/kg BT-vancomycina
Time (h)
Concn (M) (mean SEM)a
BT-vancomycin/
vancomycin ratioVancomycin BT-vancomycin
1 1.04 0.14 4.89 1.08b 4.7
6 1.73 0.13 11.41 1.79c 6.6
12 1.51 0.15 8.06 1.46c 5.3
24 0.97 0.09 3.15 0.49b 3.3
72 0.35 0.10 4.31 0.63c 12.3
168 0.08 0.05 3.73 0.61c 46.6
a n 5 rats per group.
b Significantly higher than results for vancomycin (P 0.01).
c Significantly higher than results for vancomycin (P 0.001).
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(Table 2). PK parameters obtained after i.v. administration are
detailed in Table 3.
These data demonstrate that vancomycin and BT-vancomycin
exhibit significant differences in their PK profiles. A decrease in
total clearance (CLtot) of 13.5-fold was observed for BT-vancomy-
cin compared to vancomycin, with a 14.7-fold increase in half-life
(t1/2) allowing for a 10.8-fold enhancement in the area under the
concentration-time curve (AUC). The significant changes in the
AUC indicate a higher degree of in vivo exposure to BT-vancomy-
cin, facilitating the accumulation of drug in bone due to an en-
hanced permeation and retention effect. Consequently, BT-van-
comycin shows a longer systemic mean residence time (MRT)
than vancomycin (P 0.001). The higher MRT value of BT-van-
comycin could be due in part to a more protracted steady state in
vivo, resulting in improved delivery, dramatically increased access
into bones, and prolonged exposure in bone tissue (Table 3).
The estimates of themaximumconcentration of drug in serum
(Cmax) of vancomycin and BT-vancomycin determined in the
present study were in agreement with previously published data,
which include therapeutic peak and trough serum concentrations
of 20.7 to 27.6 M and 3.5 to 6.9 M, respectively (22).
In our experiments, levels of BT-vancomycin in bone were
above the MIC of vancomycin for up to 168 h after administra-
tion. These findings predict good antimicrobial outcomes, since
the antimicrobial activity of vancomycin is time dependent and
not concentration dependent (23).
In conclusion, our previously published work with BT-vanco-
mycin showed that this novelmolecule had in vitro activity similar
to that of vancomycin against both methicillin-resistant and me-
thicillin-susceptible S. aureus strains isolated frombone infections
(21). Additionally, BT-vancomycin was shown to be more effica-
cious than an equimolar dose of vancomycin in a rat osteomyelitis
model. However, the most efficacious dosing regimen used in
these studies (i.p. injection every 12 h for 21 days) not only was
associated with high BT-vancomycin levels in plasma but also
caused a decrease in body weight, an elevation in white blood cell
count, renal dysfunction, and evidence of tubulointerstitial ne-
phritis. Although we did not examine toxicity in the current stud-
ies, we have demonstrated enhanced accumulation in bone, even
after a single i.v. dose of an amount of BT-vancomycin equivalent
to that used in the previous study (21). Thus, with further dose
optimization, this toxicity can likely be minimized, making BT-
vancomycin a useful BT therapy for the treatment of methicillin-
resistant S. aureus (MRSA) osteomyelitis. More importantly, the
results justify future studies to assess the utility of our promising
BT agent in the context of other, less toxic antibiotics that have
activity against MRSA.
ACKNOWLEDGMENTS
At the time of these studies, K.E.M. was fully employed by Pradama, Inc.,
and owned shares of the company. W.M.P. is the founder and Chief Sci-
entific Officer of Pradama, Inc., and has partial ownership of the com-
pany. Pradama, Inc., holds a license to University of Louisville patents on
BT-2-minipeg-2-vancomycin and related chemical entities, and a patent
royalty stream to K.G.T. and W.M.P. may occur. The remaining authors
declare no competing interests.
FUNDING INFORMATION
This study was supported by funding from Pradama, Inc., to W.M.P. and
a Department of Defense Peer-Reviewed Orthopaedic Research Program
Expansion Award (W81XWH-15-1-0716) to M.S.S. and P.A.C.
REFERENCES
1. Cierny G, III. 2011. Surgical treatment of osteomyelitis. Plast Reconstr Surg
127(Suppl 1):190S–204S. http://dx.doi.org/10.1097/PRS.0b013e3182025070.
2. Chambers HF, Deleo FR. 2009. Waves of resistance: Staphylococcus au-
reus in the antibiotic era. Nat RevMicrobiol 7:629–641. http://dx.doi.org
/10.1038/nrmicro2200.
3. Lew DP, Waldvogel FA. 2004. Osteomyelitis. Lancet 364:369–379. http:
//dx.doi.org/10.1016/S0140-6736(04)16727-5.
4. Rodvold KA, McConeghy KW. 2014. Methicillin-resistant Staphylococ-
cus aureus therapy: past, present, and future. Clin Infect Dis 58(Suppl
1):S20–S27. http://dx.doi.org/10.1093/cid/cit614.
5. Darley ES, MacGowan AP. 2004. Antibiotic treatment of gram-positive
bone and joint infections. J AntimicrobChemother 53:928–935. http://dx
.doi.org/10.1093/jac/dkh191.
6. Rubinstein E, Keynan Y. 2014. Vancomycin revisited—60 years later.
Front Public Health 2:217. http://dx.doi.org/10.3389/fpubh.2014.00217.
7. Massias L, Dubois C, de Lentdecker P, Brodaty O, Fischler M, Farinotti
R. 1992. Penetration of vancomycin in uninfected sternal bone. Antimi-
TABLE 2 Comparative concentrations of vancomycin and BT-vancomycin in plasma and bone after i.p. administration of 50 mg/kg vancomycin or
63.85 mg/kg BT-vancomycin
Time (h)
Concn (M) (mean SEM)a in plasma Concn (M) (mean SEM)a in bone
BT- vancomycin/
vancomycin ratio in boneVancomycin BT-vancomycin Vancomycin BT-vancomycin
1 15.6 2.0 21.1 2.1b 7.3 0.4 56.6 8.4c 7.8
6 1.6 0.2 37.7 5.1c 7.9 1.5 58.4 9.2d 7.4
12 0.4 0.04 27.4 3.1c 0.9 0.1 42.9 11.1c 47.7
a n 5 rats per group.
b Not significantly different from results for vancomycin.
c Significantly higher than results for vancomycin (P 0.0001).
d Significantly higher than results for vancomycin (P 0.01).
TABLE 3 PK parameters in rats following i.v. administration of a single
bolus of 50 mg/kg vancomycin or 63.85 mg/kg BT-vancomycin
Parametera
Result (mean SEM) for:
Vancomycin BT-vancomycin
t1/2 (h) 1.44 0.09 21.14 4.86
d
Tmax (h) 1.00 0.00 1.00 0.00
Cmax (M) 12.63 2.38 43.82 9.45
b
AUC (h · M) 58.71 10.33 631.39 95.13c
Vz (liters/kg) 1.10 0.18 1.13 0.21
CL (liters/h/kg) 0.65 0.12 0.048 0.01c
AUMC (h · h · M) 162.63 25.67 14,225.62 3,012.66e
MRT (h) 1.93 0.17 12.45 1.63d
Vss (liters/kg) 1.32 0.35 0.80 0.25
a Tmax, time to maximum concentration of drug in serum; Vz, volume of distribution;
CL, clearance; AUMC, area under the first moment of the concentration-time curve;
Vss, volume of distribution at steady state.
b Significantly higher than results for vancomycin (P 0.05).
c Significantly higher than results for vancomycin (P 0.01).
d Significantly higher than results for vancomycin (P 0.001).
e Significantly higher than results for vancomycin (P 0.0001).
Delivery of Vancomycin to Bone
March 2016 Volume 60 Number 3 aac.asm.org 1867Antimicrobial Agents and Chemotherapy
 o
n
 August 23, 2016 by UNIV O
F KENTUCKY
http://aac.asm
.org/
D
ow
nloaded from
 
crob Agents Chemother 36:2539–2541. http://dx.doi.org/10.1128/AAC
.36.11.2539.
8. Cevher E, Orhan Z, Mülazimog˘lu L, Sensoy D, Alper M, Yildiz A,
Ozsoy Y. 2006. Characterization of biodegradable chitosan microspheres
containing vancomycin and treatment of experimental osteomyelitis
caused by methicillin-resistant Staphylococcus aureus with prepared mi-
crospheres. Int J Pharm 317:127–135. http://dx.doi.org/10.1016/j.ijpharm
.2006.03.014.
9. Smith JK, Bumgardner JD, Courtney HS, Smeltzer MS, Haggard WO.
2010. Antibiotic-loaded chitosan film for infection prevention: a prelim-
inary in vitro characterization. J Biomed Mater Res B Appl Biomater 94:
203–211. http://dx.doi.org/10.1002/jbm.b.31642.
10. Parker AC, Beenken KE, Jennings JA, Hittle L, Shirtliff ME, Bumgard-
ner JD, Smeltzer MS, Haggard WO. 2015. Characterization of local
delivery with amphotericin B and vancomycin from modified chitosan
sponges and functional biofilm prevention evaluation. J Orthop Res 33:
439–447. http://dx.doi.org/10.1002/jor.22760.
11. Yang CC, Lin CC, Liao JW, Yen SK. 2013. Vancomycin-chitosan com-
posite deposited on post porous hydroxyapatite coated Ti6Al4V implant
for drug controlled release. Mater Sci Eng C Mater Biol Appl 33:2203–
2212. http://dx.doi.org/10.1016/j.msec.2013.01.038.
12. Shinsako K, Okui Y, Matsuda Y, Kunimasa J, Otsuka M. 2008. Effects
of bead size and polymerization in PMMA bone cement on vancomycin
release. Biomed Mater Eng 18:377–385. http://dx.doi.org/10.3233/BME
-2008-0554.
13. Beenken KE, Bradney L, Bellamy W, Skinner RA, McLaren SG, Gru-
enwald MJ, Spencer HJ, Smith JK, Haggard WO, Smeltzer MS. 2012.
Use of xylitol to enhance the therapeutic efficacy of polymethylmethacry-
late-based antibiotic therapy in treatment of chronic osteomyelitis. Anti-
microb Agents Chemother 56:5839–5844. http://dx.doi.org/10.1128
/AAC.01127-12.
14. Beenken KE, Smith JK, Skinner RA, Mclaren SG, Bellamy W, Gruen-
wald MJ, Spencer HJ, Jennings JA, Haggard WO, Smeltzer MS. 2014.
Chitosan coating to enhance the therapeutic efficacy of calcium sulfate-
based antibiotic therapy in the treatment of chronic osteomyelitis. J Bio-
mater Appl 29:514–523. http://dx.doi.org/10.1177/0885328214535452.
15. Giavaresi G, Bertazzoni Minelli E, Sartori M, Benini A, Della Bora T,
Sambri V, Gaibani P, Borsari V, Salamanna F, Martini L, Nicoli Aldini
N, Fini M. 2012. Microbiological and pharmacological tests on new an-
tibiotic-loaded PMMA-based composites for the treatment of osteomy-
elitis. J Orthop Res 30:348–355. http://dx.doi.org/10.1002/jor.21531.
16. Jiang JL, Li YF, Fang TL, Zhou J, Li XL, Wang YC, Dong J. 2012.
Vancomycin-loaded nano-hydroxyapatite pellets to treat MRSA-induced
chronic osteomyelitis with bone defect in rabbits. Inflamm Res 61:207–
215. http://dx.doi.org/10.1007/s00011-011-0402-x.
17. Nasim S, Vartak AP, Pierce WM, Jr, Taylor KG, Smith N, Crooks PA.
2010. 3-O-Phosphate ester conjugates of 17--O-{1-[2-carboxy-(2-
hydroxy-4-methoxy-3-carboxamido)anilido]ethyl}1,3,5(10)-estratriene
as novel bone-targeting agents. Bioorg Med Chem Lett 20:7450–7453.
http://dx.doi.org/10.1016/j.bmcl.2010.10.023.
18. Neale JR, Richter NB, Merten KE, Taylor KG, Singh S, Waite LC,
Emery NK, Smith NB, Cai J, Pierce WM, Jr. 2009. Bone selective effect
of an estradiol conjugate with a novel tetracycline-derived bone-targeting
agent. Bioorg Med Chem Lett 19:680–683. http://dx.doi.org/10.1016/j
.bmcl.2008.12.051.
19. Pierce WM, Jr, Waite LC, Taylor KG. July 2008.Bone targeting com-
pounds for delivering agents to bone for interaction therewith.US patent
7,399,789.
20. Pierce WM, Jr, Waite LC, Taylor KG. December 2011. Bone targeting
compounds for delivering agents to bone for interaction therewith (gen-
eration 2). US patent 8,071,575.
21. Karau MJ, Schmidt-Malan SM, Greenwood-Quaintance KE, Mandrekar
J, Cai J, Pierce WM, Jr, Merten K, Patel R. 2013. Treatment of methi-
cillin-resistant Staphylococcus aureus experimental osteomyelitis with
bone-targeted vancomycin. SpringerPlus 2:329. http://dx.doi.org/10.1186
/2193-1801-2-329.
22. Lundstrom TS, Sobel JD. 2004. Antibiotics for gram-positive bacterial
infections: vancomycin, quinupristin-dalfopristin, linezolid, and dapto-
mycin. Infect Dis Clin North Am 18:651–668. http://dx.doi.org/10.1016
/j.idc.2004.04.014.
23. Rybak MJ. 2006. The pharmacokinetic and pharmacodynamic properties
of vancomycin. Clin Infect Dis 42(Suppl 1):S35–S39. http://dx.doi.org/10
.1086/491712.
24. National Research Council. 2011. Guide for the care and use of laboratory
animals, 8th ed. National Academies Press, Washington, DC.
Albayati et al.
1868 aac.asm.org March 2016 Volume 60 Number 3Antimicrobial Agents and Chemotherapy
 o
n
 August 23, 2016 by UNIV O
F KENTUCKY
http://aac.asm
.org/
D
ow
nloaded from
 
